Cargando…
SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients?
COVID-19 has had a disastrous impact on the world. Apart from at least 6 million deaths, countless COVID-19 survivors are suffering long-term physical and psychiatric morbidity. Hundreds of millions have been plunged into poverty caused by economic misery, particularly in developing nations. Early i...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Academy of Allergy, Asthma & Immunology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220855/ https://www.ncbi.nlm.nih.gov/pubmed/35752434 http://dx.doi.org/10.1016/j.jaip.2022.06.011 |
_version_ | 1784732476005941248 |
---|---|
author | Ameratunga, Rohan Leung, Euphemia Woon, See-Tarn Chan, Lydia Steele, Richard Lehnert, Klaus Longhurst, Hilary |
author_facet | Ameratunga, Rohan Leung, Euphemia Woon, See-Tarn Chan, Lydia Steele, Richard Lehnert, Klaus Longhurst, Hilary |
author_sort | Ameratunga, Rohan |
collection | PubMed |
description | COVID-19 has had a disastrous impact on the world. Apart from at least 6 million deaths, countless COVID-19 survivors are suffering long-term physical and psychiatric morbidity. Hundreds of millions have been plunged into poverty caused by economic misery, particularly in developing nations. Early in the pandemic, it became apparent certain groups of individuals such as the elderly and those with comorbidities were more likely to suffer severe disease. In addition, patients with some forms of immunodeficiency, including those with T-cell and innate immune defects, were at risk of poor outcomes. Patients with immunodeficiencies are also disadvantaged as they may not respond optimally to COVID-19 vaccines and often have pre-existing lung damage. SARS-CoV-2 Omicron (B.1.529) and its subvariants (BA.1, BA.2, etc) have emerged recently and are dominating COVID-19 infections globally. Omicron is associated with a reduced risk of hospitalization and appears to have a lower case fatality rate compared with previous SARS-CoV-2 variants. Omicron has offered hope the pandemic may finally be coming to an end, particularly for vaccinated, healthy individuals. The situation is less clear for individuals with vulnerabilities, particularly immunodeficient patients. This perspective offers insight into potential implications of the SARS-CoV-2 Omicron variant for patients with immunodeficiencies. |
format | Online Article Text |
id | pubmed-9220855 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Academy of Allergy, Asthma & Immunology |
record_format | MEDLINE/PubMed |
spelling | pubmed-92208552022-06-24 SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients? Ameratunga, Rohan Leung, Euphemia Woon, See-Tarn Chan, Lydia Steele, Richard Lehnert, Klaus Longhurst, Hilary J Allergy Clin Immunol Pract Review and Feature Article COVID-19 has had a disastrous impact on the world. Apart from at least 6 million deaths, countless COVID-19 survivors are suffering long-term physical and psychiatric morbidity. Hundreds of millions have been plunged into poverty caused by economic misery, particularly in developing nations. Early in the pandemic, it became apparent certain groups of individuals such as the elderly and those with comorbidities were more likely to suffer severe disease. In addition, patients with some forms of immunodeficiency, including those with T-cell and innate immune defects, were at risk of poor outcomes. Patients with immunodeficiencies are also disadvantaged as they may not respond optimally to COVID-19 vaccines and often have pre-existing lung damage. SARS-CoV-2 Omicron (B.1.529) and its subvariants (BA.1, BA.2, etc) have emerged recently and are dominating COVID-19 infections globally. Omicron is associated with a reduced risk of hospitalization and appears to have a lower case fatality rate compared with previous SARS-CoV-2 variants. Omicron has offered hope the pandemic may finally be coming to an end, particularly for vaccinated, healthy individuals. The situation is less clear for individuals with vulnerabilities, particularly immunodeficient patients. This perspective offers insight into potential implications of the SARS-CoV-2 Omicron variant for patients with immunodeficiencies. American Academy of Allergy, Asthma & Immunology 2022-09 2022-06-22 /pmc/articles/PMC9220855/ /pubmed/35752434 http://dx.doi.org/10.1016/j.jaip.2022.06.011 Text en © 2022 American Academy of Allergy, Asthma & Immunology. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review and Feature Article Ameratunga, Rohan Leung, Euphemia Woon, See-Tarn Chan, Lydia Steele, Richard Lehnert, Klaus Longhurst, Hilary SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients? |
title | SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients? |
title_full | SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients? |
title_fullStr | SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients? |
title_full_unstemmed | SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients? |
title_short | SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients? |
title_sort | sars-cov-2 omicron: light at the end of the long pandemic tunnel or another false dawn for immunodeficient patients? |
topic | Review and Feature Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220855/ https://www.ncbi.nlm.nih.gov/pubmed/35752434 http://dx.doi.org/10.1016/j.jaip.2022.06.011 |
work_keys_str_mv | AT ameratungarohan sarscov2omicronlightattheendofthelongpandemictunneloranotherfalsedawnforimmunodeficientpatients AT leungeuphemia sarscov2omicronlightattheendofthelongpandemictunneloranotherfalsedawnforimmunodeficientpatients AT woonseetarn sarscov2omicronlightattheendofthelongpandemictunneloranotherfalsedawnforimmunodeficientpatients AT chanlydia sarscov2omicronlightattheendofthelongpandemictunneloranotherfalsedawnforimmunodeficientpatients AT steelerichard sarscov2omicronlightattheendofthelongpandemictunneloranotherfalsedawnforimmunodeficientpatients AT lehnertklaus sarscov2omicronlightattheendofthelongpandemictunneloranotherfalsedawnforimmunodeficientpatients AT longhursthilary sarscov2omicronlightattheendofthelongpandemictunneloranotherfalsedawnforimmunodeficientpatients |